GNH USA

Europe — EMA

Itulazax

GNH USA supplies Itulazax (Betula verrucosa), an allergen extract for allergic rhinitis caused by birch pollen. Request a quote for global supply today.

Betula Verrucosa (108)

Request sourcing

1
Pack/s

What is Betula Verrucosa (108)?

Betula verrucosa, the active ingredient in Itulazax, is an allergen extract presented as a sublingual formulation for sublingual use. It is employed to treat allergic rhinitis caused by birch (Betula verrucosa) pollen in sensitized individuals, administered under medical supervision to induce tolerance.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for allergen immunotherapy products. The company adheres to Good Distribution Practice, provides temperature‑controlled shipping where required, and supports regulatory documentation for importers.

What is Betula Verrucosa (108) used for?

Itulazax is used in allergy immunotherapy to address birch pollen‑induced allergic rhinitis.

Allergic rhinitis due to Betula verrucosa pollen: reduces nasal congestion, sneezing and itching. Seasonal allergic rhinoconjunctivitis caused by birch pollen: improves overall symptom control. Birch pollen‑induced allergic conjunctivitis: alleviates eye irritation and redness.

What are the side effects of Betula Verrucosa (108)?

Common Side Effects: - Oral itching or mild irritation - Throat discomfort or mild swelling of the lips - Transient nasal irritation or sneezing - Mild headache - Temporary gastrointestinal discomfort - Mild urticaria at the site of administration

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction - Angioedema affecting face or airway - Severe bronchospasm or respiratory distress - Generalized urticaria or hives - Eosinophilic esophagitis - Cardiovascular collapse in extreme cases

What precautions apply to Betula Verrucosa (108)?

Before initiating therapy, clinicians should evaluate patient suitability and monitor for reactions.

Assess patient allergy history: confirm documented sensitivity to Betula verrucosa before starting. Monitor for local reactions: observe for oral itching or swelling after the first dose. Avoid use in uncontrolled asthma: risk of bronchospasm may be heightened. Do not combine with other allergen immunotherapy without specialist guidance. Pregnancy and lactation: use only if clearly needed after risk‑benefit discussion with a physician. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Betula Verrucosa (108) interact with?

Itulazax may interact with certain medications; careful assessment is required.

Major Interactions (Avoid): - Concurrent use of beta‑blockers: may mask anaphylaxis symptoms. - ACE inhibitors: increase risk of angioedema. - Other sublingual immunotherapy products: may amplify immune response.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce local reaction, timing may need adjustment. - Systemic corticosteroids: may suppress the intended immunologic response. - Immunosuppressive agents: may diminish efficacy of the desensitization process.

Frequently asked questions

What is Itulazax used for?+
Itulazax is prescribed for the treatment of allergic rhinitis caused by Betula verrucosa (birch) pollen. It works as a sublingual allergen extract to help patients develop tolerance and reduce nasal and ocular symptoms associated with birch pollen exposure.
How does Betula verrucosa work in Itulazax?+
Betula verrucosa in Itulazax provides controlled sublingual exposure to the birch pollen allergen. This repeated exposure shifts the immune response from an IgE‑driven allergy toward a more tolerant IgG4 profile and modulates T‑cell activity, thereby decreasing hypersensitivity over time.
What is the usual dose of Itulazax?+
The dosing regimen for Itulazax is determined by the prescribing physician based on the patient’s sensitivity, age, and clinical response. The prescriber will set the initial dose and any subsequent titration steps according to established allergy immunotherapy protocols.
Is Itulazax safe to use during pregnancy or breastfeeding?+
Safety data for Itulazax in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.
How do I order Itulazax from GNH USA?+
To order Itulazax, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Itulazax compare with other birch pollen immunotherapy options?+
Itulazax is a sublingual formulation, offering a non‑injectable route compared with traditional subcutaneous birch pollen extracts. This can improve patient convenience and adherence, while delivering comparable immunologic tolerance when administered under medical supervision.
What are the storage and handling requirements for Itulazax?+
Itulazax should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. No refrigeration is required, but keep the container tightly closed to maintain stability.
How is Itulazax administered?+
Itulazax is administered sublingually. The patient places the prescribed dose under the tongue and holds it for the recommended time before swallowing, following the specific instructions provided by the prescribing clinician.
What are the most serious risks associated with Itulazax?+
The most serious risks include systemic allergic reactions such as anaphylaxis, severe bronchospasm, and angioedema. Patients should be observed after the first dose and instructed to seek immediate medical attention if they experience any signs of a severe reaction.
Who should not use Itulazax?+
Itulazax is contraindicated in individuals with a known hypersensitivity to Betula verrucosa extract, those with uncontrolled asthma, or patients who have experienced severe systemic reactions to previous allergen immunotherapy. A healthcare professional should evaluate suitability before prescribing.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Betula Verrucosa (108)
Route
Sublingual Use
Manufacturer
Alk-Abello A/S
Origin
EU

Related products